Think your coverage is unaffordable? Watch out for this Obamacare pitfall
Obamacare’s exchanges are requiring working Americans to grasp minute details of their employers’ health plans in order to avoid a nasty surprise from the IRS.
Health Care & Life Sciences
Articles
How Obamacare is affecting employers
Indiana companies are planning different methods to adapt to the health care landscape next year.
Health law fuels modest rise in costs
It’s long been known that Obamacare would make health benefits more expensive for most employers. Now, it’s finally becoming clearer by how much: about 9 percent, on average, according to a series of actuarial studies.
Insurers brainstorm with Obama staff on health exchange fix
The heads of WellPoint Inc., Aetna Inc. and at least 10 other insurers met with the Obama administration Wednesday to discuss correcting flaws in how data from the U.S. health-care marketplaces is transferred to the companies.
Franciscan hospitals to eliminate 925 full-time positions
The Indiana-based system that operates three hospitals in the Indianapolis area said it is trying to cut its expenses by as much as $500 million, or 20 percent.
Evansville suburb making pitch for IU medical center
A proposal calls for a medical education center that’s being developed by IU, the University of Evansville, the University of Southern Indiana and Ivy Tech Community College.
State medical institute snares $30M grant from feds
A consortium of Indiana University, Purdue University and University of Notre Dame can operate for another five years with the grant funds.
Insurer CEOs head to White House to talk Obamacare troubles
Health insurance execs, including WellPoint Inc. CEO Joseph Swedish, will meet with top White House officials Wednesday as the president seeks to contain political damage from the disastrous rollout of Obamacare.
Lilly’s profit soars as Cymbalta nears patent expiration
Excluding a one-time payment from a year ago, Eli Lilly and Co.’s third-quarter profit easily beat Wall Street’s expectations.
WellPoint’s profit drops, but whips expectations
The giant health insurer raised its full-year profit forecast 40 cents per share, emboldened by stabilized customer rolls and slowing medical claims.
Builders of Obama’s health website saw red flags
The government spent at least $394 million in contracts to build the federal health care exchange and data hub. The painfully slow and often unresponsive website has frustrated Americans trying to enroll for insurance plans.
Is lack of competition hiking Indiana exchange premiums?
Only four health insurers are offering policies in the Obamacare exchange in Indiana, whereas 17 have withdrawn from the market since 2010.
VC headwinds continue for life sciences firms
Indiana life sciences companies trying to raise venture capital continue to do so with a national wind in their faces, according to the third-quarter venture capital data.
Coverage gap in state may leave 182,000 uninsured
A new report that 182,000 low-income residents could go without health insurance is refocusing attention on whether Indiana will win an exception to expand Medicaid using the Healthy Indiana Plan.
Indiana’s insurance exchanges are pricey
The premiums offered by health insurers participating in the Obamacare exchanges put Indiana among the 10 most-expensive states in the country, according to data released last month by the U.S. Department of Health and Human Services.
State will lose $63M in tobacco payments in 2014
An arbitration panel found that the state hadn’t worked hard enough to collect funds from cigarette companies. The money is used to fund health programs in Indiana.
Republicans making same old mistake on health reform
Rather than railing incessantly against Obamacare, Republicans would do themselves and the country a favor if they finally agreed on a common alternative for fixing the health care system.
Analysts: Investors wrong to dump Endocyte
Investors on Friday dumped shares of West Lafayette-based Endocyte Inc. after an independent analysis said an experimental lung cancer drug is unlikely to be declared superior to existing chemotherapy. But two analysts say, to the contrary, the analysis shows the prospects for Endocyte’s drug are as good as ever.
Finding where the money is in health care
More than half of the $2.5 trillion consumers spend annually on health care in the United States flows to hospitals and doctors, with drug companies and health insurers trailing well behind.
Lilly stock shrugs off analyst downgrade
The drugmaker has become too reliant on its remaining pipeline of drugs under development for growth as it deals with patent expirations to big sellers and drug-development setbacks, a Jefferies analyst wrote.